Application of the trak-C™ HCV core assay for monitoring antiviral activity in HCV replication systems

Journal of Virological Methods

Volumn 118, Issue 1, 2004, Pages 23-31

  Cagnon, Laurence ^a   Wagaman, Pamela ^a   Bartenschlager, Ralf ^b   Pietschmann, Thomas ^b   Gao, Tiejun ^c   Kneteman, Norman M ^c   Tyrrell, David L J ^c   Bahl, Chander ^d   Niven, Patrick ^d   Lee, Stephen ^d   Simmen, Kenneth A ^a,e  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KMT Hepatech Inc   (Canada)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

^e TIBOTEC BVBA   (Belgium)

Author keywords

Antiviral assay; HCV core; HCV replicon; Interferon

Indexed keywords

ALPHA INTERFERON; MONOCLONAL ANTIBODY; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CONTROLLED STUDY; GENE AMPLIFICATION; GENOME; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; KINETICS; MOLECULAR CLONING; MONITORING; PRIORITY JOURNAL; PROTEIN PURIFICATION; SCID MOUSE; TRANSGENIC MOUSE; VIRUS CORE; VIRUS DETECTION; VIRUS EXPRESSION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CLONE CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; MICE; MICE, SCID; MICE, TRANSGENIC; SENSITIVITY AND SPECIFICITY; VIRAL CORE PROTEINS; VIREMIA; VIROLOGY; VIRUS REPLICATION;

HEPATITIS C VIRUS; MURINAE;

EID: 2442599904     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2004.01.014     Document Type: Article

References (30)

1. Aoyagi K., Iida K., Ohue C., Matsunaga Y., Tanaka E., Kiyosawa K., Yagi S. Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection. Clinical Laboratory (Heidelberg Germany). 47:2001;119-127
2. Aoyagi K., Ohue C., Iida K., Kimura T., Tanaka E., Kiyosawa K., Yagi S. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J. Clin. Microbiol. 37:1999;1802-1808
3. Bartenschlager R. Hepatitis C virus replicons: potential role for drug develoment. Nature Rev. Drug Discovery. 1:2002;911-916
4. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science. 290:2000;1972-1974
5. Bouvier-Alias M., Patel K., Dahari H., Beaucourt S., Larderie P., Blatt L., Hezode C., Picchio G., Dhumeaux D., Neumann A.U., McHutchison J.G., Pawlotsky J.M. Clinical utility of total hepatitis C virus (HCV) core antigen quantification, a new indirect marker of HCV replication. Hepatology. 36:2002;211-218
6. Bukh J., Pietschmann T., Lohmann V., Krieger N., Faulk K., Engle R.E., Govindarajan S., Shapiro M., St. Claire M., Bartenschlager R. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc. Natl. Acad. Sci. U.S.A. 99:2003;14416-14421
7. Castet V., Fournier C., Soulier A., Brillet R., Coste J., Larrey D., Dhumeaux D., Maurel P., Pawlotsky J.M. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J. Virol. 76:2002;8189-8199
8. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362
9. Chung R.T., He W., Saquib A., Contreras A.M., Xavier R.J., Chawla A., Wang T.C., Schmidt E.V. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc. Natl. Acad. Sci. U.S.A. 98:2001;9847-9852
10. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H.J., Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U.S.A. 93:1996;15394-15399
11. Frese M., Pietschmann T., Moradpour D., Haller O., Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82:2001;723-733
12. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., Bartenschlager R. Interferon-gamma inhibits replication of subgeneomic and genomic hepatitis C virus RNAs. Hepatology. 35:2002;694-703
13. Friebe P., Lohmann V., Krieger N., Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 75:2001;12047-12057
14. Guo J.-T., Bichko V.V., Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:2001;8516-8523
15. Ikeda M., Yi M., Li K., Lemon S.M. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J. Virol. 76:2002;2997-3006
16. Krieger N., Lohmann V., Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:2001;4614-4624
17. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345:2001;41-52
18. Leigh J.P., Bowlus C.L., B. Leistikow N., Schenker M. Costs of hepatitis C. Arch. Intern. Med. 161:2001;2231-2237
19. Lohmann V., Korner F., Dobierzewska A., Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:2001;1437-1449
20. Lohmann V., Korner F., Koch J.O., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113
21. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nature Med. 7:2001;927-933
22. Pietschmann T., Lohmann V., Kaul A., Krieger N., Rinck G., Rutter G., Strand D., Bartenschlager R. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J. Virol. 76:2002;4008-4021
23. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:2001;1252-1264
24. Ross R.S., Viazov S., Sarr S., Hoffmann S., Kramer A., Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J. Virol. Methods. 101:2002;159-168
25. Schiff E.R., de Medina M., Kahn R.S. New perspectives in the diagnosis of hepatitis C. Sem. Liver Dis. 19:1999;3-15
26. Schinazi R.F., Ilan E., Black P.L., Yao X., Dagan S. Cell-based and animal models for hepatitis B and C viruses. Antiviral Chem. Chemother. 10:1999;99-114
27. Tanaka E., Ohue C., Aoyagi K., Yamaguchi K., Yagi S., Kiyosawa K., Alter H.J. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology. 32:2000;388-393
28. World Health Organization 1999. Hepatitis C-global prevalence (update). Weekly Epidemiol. Record 74, 425-427.
29. Zanetti A.R., Romano L., Brunetto M., Colombo M., Bellati G., Tackney C. Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J. Med. Virol. 70:2003;27-30
30. Zein N.N. Experimental and emerging therapies for chronic hepatitis C virus infection. Expert Opin. Invest. Drugs. 10:2001;1457-1469